Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188432 · ClinicalTrials.gov registry record · Phase 2
Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase 2 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT03188432 is a Phase 2 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 50 participants.
The verdict
NCT03188432, a Phase 2 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may help the drugs get into the cancer cells better, minimize the toxicity of the drugs on normal cells, and help to kill any cancer cells left over after surgery.
Interventions
- DRUG Carboplatin
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- PROCEDURE Cytoreductive Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-01-02 |
| Est. Completion | 2024-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188432
The ClinicalTrials.gov registry entry for NCT03188432 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT03188432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188432 about?
NCT03188432 is a clinical study titled "Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". This phase II trial studies how well hyperthermic intraperitoneal chemotherapy works in improving quality of life in patients with stage IIIC-IV ovarian, fallopian tube, or primary peritoneal cancer. In hyperthermic intraperitoneal chemotherapy, the chemotherapy is warmed before being used and may h...
What is the current status of trial NCT03188432?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2019-01-02. Estimated completion is 2024-02-08.
What interventions are being tested in trial NCT03188432?
The interventions under investigation include: Carboplatin (DRUG), Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Cytoreductive Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT03188432?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.